Thienopyridine kinase inhibitors

Abstract

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

1 . A compound of formula (I)  
       
         
           
           
               
               
           
         
       
       or a therapeutically acceptable salt thereof, wherein 
 R 1  is selected from the group consisting of hydrogen, alkenyl, alkoxyalkynyl, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkynyl, alkyl, alkynyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, aryloxyalkyl, aryloxyalkynyl, arylsulfanylalkyl, arylsulfanylalkynyl, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, cyanoalkyl, cyanoalkynyl, cycloalkylalkynyl, formylalkenyl, formylalkyl, halo, haloalkyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heteroarylalkynyl, heteroarylcarbonylalkenyl, heteroarylcarbonylalkyl, heterocyclylalkenyl, heterocyclylalkyl, heterocyclylalkynyl, heterocyclylcarbonylalkenyl, heterocyclylcarbonylalkyl, hydroxyalkenyl, hydroxyalkyl, hydroxyalkynyl, NR a R b , (NR a R b )alkenyl, (NR a R b )alkyl, (NR a R b )alkynyl, (NR a R b )carbonylalkenyl, (NR a R b )carbonylalkyl, (NR a R b )carbonylalkynyl, nitro, nitroalkenyl, nitroalkyl, and nitroalkynyl;  
 R 2  is selected from the group consisting of hydrogen and alkyl;  
 R 3  is selected from the group consisting of halo, aryl, heteroaryl, and heterocyclyl, wherein the aryl, the heteroaryl, and the heterocyclyl are optionally substituted with one, two, or three substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxy, hydroxyalkyl, LR 4 , and NR a R b ; provided that at least two of the three substituents are other than LR 4 ;  
 L is selected from the group consisting of 0, (CH 2 ) m C(O)NR 5 , NR 5 C(O)(CH 2 ) m , NR 5 SO 2 , SO 2 NR 5 , and (CH 2 ) m N(R 56 )C(O)N(R 6 )(CH 2 )., wherein m and n are independently 0 or 1, and wherein each group is drawn with its right end attached to R 4 ;  
 R 4  is selected from the group consisting of aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; and  
 R 5  and R 6  are independently selected from the group consisting of hydrogen and alkyl.  
 
     
     
         2 . The compound of  claim 1  wherein R 3  is selected from the group consisting of halo, heteroaryl, and heterocyclyl.  
     
     
         3 . The compound of  claim 1  wherein R 3  is aryl.  
     
     
         4 . The compound of  claim 3  wherein R 3  is aryl, wherein the aryl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NR a R b .  
     
     
         5 . The compound of  claim 3  wherein R 3  is aryl, wherein the aryl is substituted with LR 4  and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NR a R b .  
     
     
         6 . The compound of  claim 5  wherein L is O.  
     
     
         7 . The compound of  claim 6  wherein R 1  is selected from the group consisting of heterocyclylalkenyl, heterocyclylcarbonylalkenyl, (NR a R b )alkenyl, and (NR a R b )carbonylalkenyl.  
     
     
         8 . The compound of  claim 6  wherein R 1  is selected from the group consisting of hydrogen, alkoxycarbonylalkenyl, carboxyalkenyl, heteroaryl, and hydroxyalkenyl.  
     
     
         9 . The compound of  claim 5  wherein L is selected from the group consisting of NR 5 C(O)(CH 2 ) m  and NR 5 SO 2 .  
     
     
         10 . The compound of  claim 9  wherein R 1  is (NR a R b )alkenyl.  
     
     
         11 . The compound of  claim 9  wherein R 1  is selected from the group consisting of heterocyclylalkenyl, heterocyclylalkyl, and (NR a R b )carbonylalkenyl.  
     
     
         12 . The compound of  claim 9  wherein R 1  is selected from the group consisting of hydrogen, alkoxycarbonylalkenyl, carboxyalkenyl, formylalkenyl, and heteroaryl.  
     
     
         13 . The compound of  claim 9  wherein R 1  is selected from the group consisting of alkoxyalkynyl, arylalkynyl, carboxyalkynyl, cycloalkylalkynyl, halo, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkynyl, hydroxyalkynyl, and (NR a R b )alkynyl.  
     
     
         14 . The compound of  claim 5  wherein L is (CH 2 ) m N(R 5 )C(O)N(R 6 )(CH 2 ) n .  
     
     
         15 . The compound of  claim 14  wherein R 1  is selected from the group consisting of alkynyl, arylalknyl, aryloxyalkynyl, arylsulfanylalkynyl, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NR a R b )alkynyl.  
     
     
         16 . The compound of  claim 14  wherein R 1  is selected from the group consisting of alkoxycarbonylalkenyl, carboxyalkenyl, heteroarylcarbonylalkenyl, heterocyclylcarbonylalkenyl, and (NR a R b )carbonylalkenyl.  
     
     
         17 . The compound of  claim 14  wherein R 1  is selected from the group consisting of aryl and heteroaryl.  
     
     
         18 . The compound of  claim 14  wherein R 1  is selected from the group consisting of alkoxycarbonylalkyl, carboxyalkyl, heterocyclylalkyl, hydroxyalkyl, (NR a R b )alkyl, and (NR a R b )carbonylalkyl.  
     
     
         19 . The compound of  claim 14  wherein R 1  is selected from the group consisting of hydrogen, halo, nitro, and NR a R b .  
     
     
         20 . A compound which is 
 (2E)-3-[4-amino-3-(3-phenoxy-1-propynyl)thieno[3,2-c]pyridin-7-yl]-N-methylacrylamide.    
     
     
         21 . A compound selected from the group consisting of 
 N-{4-[4-amino-7-(3-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N′-(3-methylphenyl)urea;    N-{4-[4-amino-7-(2-methoxy-5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N′-[3-(trifluoromethyl)phenyl]urea;    N-{4-[4-amino-7-(5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N′-(3-methylphenyl)urea;    N-(4-{4-amino-7-[3-(diethylamino)-1-propynyl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-methylphenyl)urea;    N-(4-{4-amino-7-[3-(methylamino)-1-propynyl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-methylphenyl)urea;    N-{4-[4-amino-7-((1E)-3-{4-[3-(dimethylamino)propyl]-1-piperazinyl}-1-propenyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-1-methyl-1H-indole-2-carboxamide;    N-[4-(4-amino-7-{(1E)-3-[4-(aminomethyl)-1-piperidinyl]-1-propenyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide;    1-{(2E)-3-[4-amino-3-(3-methoxy-4-{[(1-methyl-1H-indol-2-yl)carbonyl]amino}phenyl)thieno[3,2-c]pyridin-7-yl]-2-propenyl}-4-piperidinecarboxylic acid;    N-[4-(4-amino-7-{(1E)-3-[trans-(4-aminocyclohexyl)amino]-1-propenyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide; and    N-(4-{4-amino-7-[(1E)-3-(4-amino-1-piperidinyl)-1-propenyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide.    
     
     
         22 . A compound selected from the group consisting of N-{4-[4-amino-7-(4-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea; 
 N-{4-[4-amino-7-(4-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N′-(2-fluoro-5-methylphenyl)urea;    N-(4-{4-amino-7-[(1E)-3-(4-hydroxy-1-piperidinyl)-1-propenyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide; and    N-[4-(4-amino-7-{(1E)-3-[4-(2-hydroxyethyl)-1-piperazinyl]-1-propenyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide.    
     
     
         23 . A pharmaceutical composition comprising a compound of  claim 1  or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.  
     
     
         24 . A method for inhibiting one or more protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of  claim 1 , or a therapeutically acceptable salt thereof.  
     
     
         25 . The method of  claim 24  wherein the protein kinases are selected from the group consisting of KDR, Ckit, CSF-1R, PDGFRβ, PDGFRα, Flt-i, Flt-3, Flt-4, Tie-2, Lck, Src, Fyn, Lyn, Blk, Hck, Fgr, Cot, and Yes.  
     
     
         26 . The method of  claim 25  wherein the protein kinases are selected from the group consisting of KDR and Lck.  
     
     
         27 . A method for treating a condition in a patient comprising administering a therapeutically effective amount of a compound of  claim 1 , or a therapeutically acceptable salt thereof, to the patient, wherein the condition is selected from the group consisting of an ocular condition, a cardiovascular condition, a cancer, Crow-Fukase (POEMS) syndrome, a diabetic condition, sickle cell anemia, chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, graft rejection, lyme disease, sepsis, von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, polycystic kidney disease, fibrosis, sarcoidosis, cirrhosis, thyroditis, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic occlusive pulmonary disease, asthma or edema following burns, trauma, radiation, stroke, hypoxia, ischemia, overian hyperstimulation syndrome, preecampsia, menometrorrhagia, endometriosis, or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxyvirus, protozoa, and toxoplasmosis.  
     
     
         28 . The method of  claim 27  wherein the condition is a cancer.